文献速递儿科影像技术与安全MR

儿童静脉注射钆基对比剂急性过敏样反应的发生频率与严重程度

Frequency and Severity of Acute Allergic-Like Reactions to Intravenously Administered Gadolinium-Based Contrast Media in Children.
PubMed 文献 · Invest Radiol · 2018-01-01

该回顾性研究评估2009年1月至2017年1月儿童静脉注射钆基对比剂后急性过敏样反应的发生频率与严重程度,期间科室将主要对比剂从钆喷酸葡胺更换为钆特酸葡胺;共32,365次给药中21次(0.06%)发生过敏样反应,各对比剂间反应频率无显著差异,过渡期反应频率升高可能反映韦伯效应。

要点

  • 儿童钆基对比剂过敏样反应罕见,总体发生率为0.06%(21/32,365次给药)。
  • 钆特酸葡胺反应频率0.06%,与其他钆基对比剂无显著差异(P > 0.05)。
  • 对比剂过渡期6个月内反应频率升至0.20%,高于过渡前0.07%和过渡后0.04%。

核心结论

  • 儿童钆基对比剂过敏样反应罕见,钆特酸葡胺反应频率与其他钆基对比剂无显著差异。
  • 从钆喷酸葡胺过渡到钆特酸葡胺期间观察到报告过敏样反应频率增加,可能反映韦伯效应。

研究设计与样本

  • 回顾性研究,经机构审查委员会批准并符合《健康保险流通与责任法案》。
  • 2009年1月至2017年1月儿童患者钆基对比剂过敏样反应回顾性评估,期间科室将主要对比剂从钆喷酸葡胺更换为钆特酸葡胺。
  • 过敏样反应从科室和医院数据库识别,钆基对比剂剂量数从计费数据获取。
  • 共32,365次钆基对比剂给药:钆磷维塞三钠327次、钆塞酸二钠672次、钆特酸葡胺12,012次、钆喷酸葡胺19,354次。
  • 各钆基对比剂过敏样反应频率计算并使用卡方检验比较。

诊断标准与关键数值

  • 过敏样反应总体发生率为0.06%(21/32,365次给药)。
  • 各对比剂反应频率:钆磷维塞三钠0.3%、钆塞酸二钠0%、钆特酸葡胺0.06%、钆喷酸葡胺0.08%,组间无显著差异(P > 0.05)。
  • 反应严重程度:轻度10次(47.6%)、中度10次(47.6%)、重度1次(4.8%)。
  • 过渡期6个月内总体反应频率0.20%,高于过渡前0.07%(P = 0.048)和过渡后0.04%(P = 0.0095)。

临床应用与阅片要点

  • 儿童钆基对比剂过敏样反应总体罕见,阅片和报告中可参考总体发生率0.06%。
  • 钆特酸葡胺反应频率与钆喷酸葡胺、钆磷维塞三钠、钆塞酸二钠均无显著差异(P > 0.05)。
  • 对比剂更换过渡期报告的反应频率升高,原文认为可能反映韦伯效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The purpose of this study is to determine the frequency and severity of acute allergic-like reactions to gadolinium-based contrast media (GBCM) in children before, during, and after the transition from gadopentetate dimeglumine to gadoterate meglumine as our primary clinical GBCM.

MATERIALS AND METHODS: Institutional review board approval was obtained for this Health Insurance Portability and Accountability Act-compliant retrospective investigation. Allergic-like reactions to GBCM in pediatric patients were retrospectively assessed from January 2009 to January 2017, which included a departmental change of GBCM from gadopentetate dimeglumine to gadoterate meglumine. Allergic-like reactions were identified from departmental and hospital databases. The number of doses of GBCM was obtained from billing data. Allergic-like reaction frequencies for each GBCM were calculated and compared using the chi-squared test.

RESULTS: A total of 32,365 administrations of GBCM occurred during the study period (327 for gadofosveset trisodium; 672 for gadoxetate disodium; 12,012 for gadoterate meglumine; and 19,354 for gadopentetate dimeglumine). Allergic-like reactions occurred after 21 (0.06%) administrations. Reaction frequencies were not significantly different among the GBCM (0.3% gadofosveset trisodium; 0% gadoxetate disodium, 0.06% gadoterate meglumine, 0.08% gadopentetate dimeglumine; P > 0.05). Ten (47.6%) reactions were mild, 10 (47.6%) were moderate, and 1 (4.8%) was severe. The overall reaction frequency peaked during the 6-month transition period from gadopentetate dimeglumine to gadoterate meglumine (0.20%), compared with 0.07% pretransition (P = 0.048) and 0.04% posttransition (P = 0.0095).

CONCLUSION: Allergic-like reactions to GBCM in children are rare. Gadoterate meglumine has a reaction frequency that does not significantly differ from other GBCMs. During the transition from gadopentetate dimeglumine to gadoterate meglumine, an increase in the frequency of reported allergic-like reactions was observed, likely reflective of the Weber effect.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Forbes-Amrhein MM, Dillman JR, Trout AT, et al. Frequency and Severity of Acute Allergic-Like Reactions to Intravenously Administered Gadolinium-Based Contrast Media in Children. Invest Radiol. 2018. PMID: 29337841. doi:10.1097/RLI.0000000000000444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。